万泰生物 | 官网

Core Diagnostics

Wantai BioPharm has successfully integrated industry, academia and research experiences into vertically integrated ecosystem for development and distribution of in vitro diagnostics and automated laboratoy instruments. The company has launched the Wan600, Wan BC2800, WanTLA immunoassay and biochemistry analyzers which offer a menu of 220 chemiluminescence and biochemistry tests, including novel diagnostic tests for detection of Hepatitis virus infections, P-85 Ab for nasopharyngeal cancer screening and TB-IGRA for large population screening.

・

Intelligent Laboratory

Wantai BioPharm's Intelligent Lab Solution integrates automated equipment, AI analytics and cloud computing with 6S lean management to enable end-to-end digital transformation. This comprehensive platform enhances testing efficiency, ensures precision quality control, and supports smart hospital development while maintaining strict compliance standards.

Explore

・

Diagnostic Kits

Wantai BioPharm, in collaboration with Xiamen University, jointly established the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD). Under this institute, we have developed over 100 bioactive materials, which are integral to our diagnostic products—enabling us to achieve 80% self-sufficiency in the production of immunoassay kits.The company has also been a pioneer in developing innovative diagnostic assays, including high-value Hepatitis B core antibody tests, a urine-based Hepatitis E antigen test, Hepatitis D virus detection, IL-6, HIV 4th generation CLIA, Helicobacter pylori antibody, gastrin-17, and soluble transferrin receptor assays. These advancements highlight our strong capabilities in innovation and underscore our significant contributions to the progress of medical technology.

Explore

・

Core Diagnostic Solutions

Specializing in healthcare solutions, we offer comprehensive services including chronic disease management, integrated Hepatitis E screening and prevention, full lifecycle women's health programs, medical laboratory services, ISO 15189 accreditation consulting, lean management optimization, and regional inspection center support - delivering complete medical solutions tailored to modern healthcare needs.

Explore

Innovative Diagnostics

Wantai BioPharm offers a comprehensive range of diagnostic products including enzyme-linked immunosorbent assay (ELISA), colloidal gold, nucleic acid, and clinical laboratory quality control products. These solutions are designed for accurate clinical testing of human samples, providing reliable diagnostic results and blood screening data. Our products primarily target major infectious diseases such as HIV, Hepatitis (all types), Tuberculosis, and Influenza A/B, supporting healthcare professionals in disease detection and management.

・

Medical Instruments

Leveraging the scientific expertise of NIDVD, Wantai BioPharm has successfully developed a series of advanced nucleic acid detection systems, including the WanTag series, MFCS-6, and FMNE-08. These innovative solutions are designed to meet the diverse requirements of medical institutions across all levels, with broad applications in blood banks, disease control centers, clinical laboratories, and third-party testing facilities.

Explore

・

Diagnostic Tests

As China's largest immunodiagnostic production base and a nationally recognized demonstration unit, Wantai BioPharm has maintained market leadership with its HIV test kit ranking first in China for 16 consecutive years. The company's HCV, TP, and HBV test kits also dominate their respective markets. Building on this success, Wantai has pioneered innovative diagnostic solutions in emerging fields including viral detection and self-testing for HIV and HEV.

Explore

・

Quality Control Products

Wantai has pioneered in the development and manufacturing of third-party quality controls and offers over 150 reference materials which are produced under strict quality management system requirements and are traceable to clinical-level standards. We provide end-to-end support to medical institutions, IVD companies, and research organizations by building the concept of an integrated platform that combines research and development, production, and service.

Explore

・

Bioactive Materials

Innobiomax, a subsidiary of Wantai, is focused on the research, development, production, and sales of bioactive raw materials. We offer over 300 antigens, antibodies and core enzymes for the development of accurate immunoassays and clinical biochemistry reagents.

Explore

・

Innovative Diagnostic Solutions

As an integral player in the global healthcare sector, Wantai offers comprehensive diagnostic solutions for blood safety testing and internal quality control. Leveraging our strong research capabilities and collaboration across industry, academia, and research institutions, Wantai utilizes innovative technologies to overcome challenges and address clinical needs effectively.

Explore

Vaccines

Having been dedicated to the vaccine industry for nearly 20 years, Wantai is committed to providing high-quality, affordable and innovative vaccines for human beings. With a sustainable industry-academia-research model, the company closely collaborated with the “National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)” and established the world’s first E.coli platform for recombinant virus-like particle vaccines, and successfully launched the world’s first recombinant hepatitis E vaccine (Hecolin®) and the first HPV vaccine (Cecolin®) in the Chinese market. (the 4th HPV vaccine in the world).